Literature DB >> 20553975

Current therapeutic approaches to autoimmune chronic uveitis in children.

Gabriele Simonini1, Luca Cantarini, Cecilia Bresci, Monica Lorusso, Mauro Galeazzi, Rolando Cimaz.   

Abstract

Uveitis is an inflammatory disorder involving inflammation of the uveal tract. It is classified as anterior, intermediate, posterior or panuveitis, depending on the part of eye affected by the inflammatory process. In children, non-infectious, chronic uveitis is a relatively uncommon but serious disease, with the potential for significant long-term complications and possible blindness. Although frequently associated with an underlying systemic disease, e.g. juvenile idiopathic arthritis (JIA), a significant number of cases in children show no associated signs or symptoms, and are labelled as idiopathic. Taking into account this evidence, an anti-inflammatory therapy based on an immuno-modulatory approach seems a reasonable strategy for non-infectious chronic uveitis, in children as well as in adults. Due to a lack of controlled studies regarding uveitis in children, immunosuppressive drugs are supported only at evidence level III. The aim of this review is to report currently available medical strategies for treatment of childhood sight-threatening chronic uveitis; in addition, a step-by-step approach to the use of immunosuppressants in this context is suggested. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20553975     DOI: 10.1016/j.autrev.2010.05.017

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  24 in total

Review 1.  Juvenile idiopathic arthritis-associated uveitis.

Authors:  Ying Qian; Nisha R Acharya
Journal:  Curr Opin Ophthalmol       Date:  2010-11       Impact factor: 3.761

2.  Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis.

Authors:  Clara Molina; Consuelo Modesto; Nieves Martín-Begué; Cristina Arnal
Journal:  Clin Rheumatol       Date:  2013-07-05       Impact factor: 2.980

Review 3.  Uveitis associated with juvenile idiopathic arthritis.

Authors:  Ethan S Sen; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Nat Rev Rheumatol       Date:  2015-03-31       Impact factor: 20.543

4.  An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.

Authors:  Arjun B Sood; Sheila T Angeles-Han
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-01-29

Review 5.  Cutting-edge issues in autoimmune uveitis.

Authors:  Roger A Levy; Francisco Assis de Andrade; Ivan Foeldvari
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

6.  Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.

Authors:  Aswani Dutt Vadlapudi; Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Recent Pat Biomed Eng       Date:  2012-04-01

7.  Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis.

Authors:  Aimee O Hersh; Spencer Cope; John F Bohnsack; Akbar Shakoor; Albert T Vitale
Journal:  Ocul Immunol Inflamm       Date:  2016-12-14       Impact factor: 3.070

Review 8.  Non-Infectious Uveitis: Optimising the Therapeutic Response.

Authors:  Archana Airody; Greg Heath; Susan Lightman; Richard Gale
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

9.  Pediatric uveitis.

Authors:  Ilknur Tugal-Tutkun
Journal:  J Ophthalmic Vis Res       Date:  2011-10

10.  Lack of association between the protein tyrosine phosphatase non-receptor type 22 R263Q and R620W functional genetic variants and endogenous non-anterior uveitis.

Authors:  María Carmen Cénit; Ana Márquez; Miguel Cordero-Coma; Alejandro Fonollosa; Victor Llorenç; Joseba Artaraz; David Díaz Valle; Ricardo Blanco; Joaquín Cañal; David Salom; José Luis García Serrano; Enrique de Ramón; María José del Rio; Marina Begoña Gorroño-Echebarría; José Manuel Martín-Villa; Blanca Molins; Norberto Ortego-Centeno; Javier Martín
Journal:  Mol Vis       Date:  2013-03-20       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.